We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 04, 2019

Nivolumab Plus Ipilimumab vs Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Nivolumab Plus Ipilimumab Versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma: Extended Follow-Up of Efficacy and Safety Results From a Randomised, Controlled, Phase 3 Trial
Lancet Oncol 2019 Aug 16;[EPub Ahead of Print], RJ Motzer, BI Rini, DF McDermott, O Arén Frontera, HJ Hammers, MA Carducci, P Salman, B Escudier, B Beuselinck, A Amin, C Porta, S George, V Neiman, S Bracarda, SS Tykodi, P Barthélémy, R Leibowitz-Amit, ER Plimack, SF Oosting, B Redman, B Melichar, T Powles, P Nathan, S Oudard, D Pook, TK Choueiri, F Donskov, MO Grimm, H Gurney, DYC Heng, CK Kollmannsberger, MR Harrison, Y Tomita, I Duran, V Grünwald, MB McHenry, S Mekan, NM Tannir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading